Subcutaneous Fluid Administration
VITRASE® (hyaluronidase injection) is indicated as an
adjuvant in subcutaneous fluid administration for achieving hydration.
Dispersion And Absorption Of Injected Drugs
VITRASE is indicated as an adjuvant to increase dispersion
and absorption of other injected drugs.
VITRASE is indicated as an adjuvant in subcutaneous
urography for improving resorption of radiopaque agents.
DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for
particulate matter and discoloration prior to administration, whenever solution
and container permit.
VITRASE (hyaluronidase injection) should be administered as
discussed below, since its effects relative to absorption and dispersion of other
drugs are not produced when it is administered intravenously.
Draw the desired amount of VITRASE into the syringe to
obtain the target Hyaluronidase Activity (USP Units) according to the table
Amount of VITRASE Solution Withdrawn Per Target Hyaluronidase
|Target Hyaluronidase Activity (USP Units)
||Volume Withdraw from Vial (mL)
After admixture with drug, store at 15 to 25°C (59 to 77°F)
and use within 6 hours.
Subcutaneous Fluid Administration (Hypodermoclysis)
Insert needle with aseptic precautions. With tip free and
movable between skin and muscle, begin clysis; fluid should start in readily
without pain or lump. Then inject VITRASE (hyaluronidase injection) into rubber
tubing close to needle.
An alternate method is to inject VITRASE under skin prior to
clysis. 200 Units will facilitate absorption of 1,000 mL or more of solution.
As with all parenteral fluid therapy, observe effect closely, with same
precautions for restoring fluid and electrolyte balance as in intravenous
injections. The dose, the rate of injection, and the type of solution (saline, glucose,
Ringer's etc.) must be adjusted carefully to the individual patient. When solutions
devoid of inorganic electrolytes are given by hypodermoclysis, hypovolemia may occur.
This may be prevented by using solutions containing adequate amounts of
inorganic electrolytes and/or controlling the volume and speed of
VITRASE may be added to small volumes of solution (up to 200
mL), such as small clysis for infants or solutions of drugs for subcutaneous
injection. For infants and children less than 3 years old, the volume of a
single clysis should be limited to 200 mL; and in premature infants or during
the neonatal period, the daily dosage should not exceed 25 mL/kg of body
weight; the rate of administration should not be greater than 2 mL per minute.
For older patients, the rate and volume of administration should not exceed
those employed for intravenous infusion.
Absorption And Dispersion Of Injected Drugs
Absorption and dispersion of other injected drugs may be
enhanced by adding 50 – 300 Units, most typically 150 Units of VITRASE
hyaluronidase to the injection solution.
The subcutaneous route of administration of urographic
contrast media is indicated when intravenous administration cannot be
successfully accomplished,Â particularly in infants and small children. With
the patient prone, 75 Units of VITRASE (hyaluronidase injection) is injected
subcutaneously over each scapula, followed by injection of the contrast medium
at the same sites.
Dosage Forms And Strengths
Ovine hyaluronidase 200 USP Units/mL single use vials
Storage And Handling
VITRASE® (hyaluronidase injection)Â Ovine is supplied
sterile as 200 USP Units/ mL of ovine hyaluronidase non-preserved,Â 1.2 mL in a
single-use 2 mL glass vial with a rubber stopper and aluminum seal.
- Protect from light.
- Store unopened vial in refrigerator at 2° to 8°C (35° to
- Do not freeze.
Distributed by: Bausch & Lomb Incorporated,Â Tampa, FL 33637. Manufactured by: Alliance Medical Products,Â Inc., CA 92618. Revised: Oct 2014